Received Jan 22, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | 5G422 | — |
administration of Shingrix with a sterile diluent; administration of Shingrix with a sterile diluent; This non-serious case was reported by a nurse via call center representative and described the occurrence of wrong solution used in drug reconstitution in a patient who received Herpes zoster (Shingrix) (batch number 5G422, expiry date JUL-2027) for prophylaxis. On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced wrong solution used in drug reconstitution (Verbatim: administration of Shingrix with a sterile diluent) and inappropriate dose of drug administered (Verbatim: administration of Shingrix with a sterile diluent). The outcome of the wrong solution used in drug reconstitution and inappropriate dose of drug administered were not applicable. Additional Information: GSK Receipt Date: 20-JAN-2026 The nurse called on 20 Jan 2026 to report that Shingrix had been administered with a sterile diluent. She asked whether, if the antigen component had been used without the suspension (without the green cap), it meant that the patient had not received the full dose.